Literature DB >> 24266913

Chronic hepatitis B virus infection.

Brian J McMahon1.   

Abstract

All providers, regardless of specialty, should perform screening for HBV on high-risk persons, especially those born in endemic countries. The primary care physician can perform the initial evaluation and follow-up of patients with chronic HBV by following the algorithm in this article and consulting with specialists when appropriate. Chronically infected patients should be followed on a regular basis, preferably every 6 months, with liver function tests, and when appropriate, HBV DNA levels. Those who meet the criteria for high risk for HCC should undergo liver ultrasound every 6 months. Powerful antiviral medications are available that can suppress but not cure HBV and result in resolution of liver inflammation and fibrosis, even cirrhosis, as well as decrease the risk of developing HCC. They should be used in those patients who meet the criteria outlined in the practice guidelines of the major liver societies.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic hepatitis B; Management; Natural history

Mesh:

Substances:

Year:  2013        PMID: 24266913     DOI: 10.1016/j.mcna.2013.08.004

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  22 in total

Review 1.  Progress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseases.

Authors:  Samantha A Nicholson; Buhle Moyo; Patrick B Arbuthnot
Journal:  World J Hepatol       Date:  2015-04-28

2.  Diabetes and prediabetes in patients with hepatitis B residing in North America.

Authors:  Mandana Khalili; Manuel Lombardero; Raymond T Chung; Norah A Terrault; Marc G Ghany; W Ray Kim; Daryl Lau; Mauricio Lisker-Melman; Arun Sanyal; Anna S Lok
Journal:  Hepatology       Date:  2015-09-29       Impact factor: 17.425

3.  Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B.

Authors:  Mandana Khalili; Margaret C Shuhart; Manuel Lombardero; Jordan J Feld; David E Kleiner; Raymond T Chung; Norah A Terrault; Mauricio Lisker-Melman; Arun Sanyal; Anna S Lok
Journal:  Diabetes Care       Date:  2018-03-29       Impact factor: 19.112

4.  Unveiling the roles of HBV polymerase for new antiviral strategies.

Authors:  Daniel N Clark; Jianming Hu
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

Review 5.  Current and future antiviral drug therapies of hepatitis B chronic infection.

Authors:  Lemonica Koumbi
Journal:  World J Hepatol       Date:  2015-05-18

6.  Adherence to chronic hepatitis B screening guidelines for persons from intermediate to high prevalence Countries.

Authors:  Ermias Diro; Maria A Corcorran; Kristine Lan; Ayushi Gupta; H Nina Kim
Journal:  J Community Health       Date:  2022-05-19

Review 7.  Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis.

Authors:  Konstantinos Mantzoukis; Manuel Rodríguez-Perálvarez; Elena Buzzetti; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-21

8.  Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review).

Authors:  Chaohui Zuo; Man Xia; Qunfeng Wu; Haizhen Zhu; Jingshi Liu; Chen Liu
Journal:  Oncol Lett       Date:  2014-11-21       Impact factor: 2.967

9.  Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection.

Authors:  Yongmei Zhang; Richeng Mao; Ran Yan; Dawei Cai; Yijun Zhang; Haoxiang Zhu; Yaoyue Kang; Hongyan Liu; Jinyu Wang; Yanli Qin; Yuxian Huang; Haitao Guo; Jiming Zhang
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

10.  Liver resection for young patients with large hepatocellular carcinoma: a single center experience from China.

Authors:  Xi-yu Liu; Jiang-feng Xu
Journal:  World J Surg Oncol       Date:  2014-06-03       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.